Prescription ·Strong evidence ·Reviewed May 2026
Valganciclovir is an oral prodrug of ganciclovir used to prevent and treat cytomegalovirus (CMV) disease, most often in solid-organ transplant recipients and in people with advanced HIV. After absorption it is rapidly converted to ganciclovir, which provides oral ganciclovir exposure comparable to intravenous dosing. Because of significant bone marrow and reproductive toxicity, it requires careful blood-count monitoring and dose adjustment for renal function.
The bottom line
Evidence rating strong. Most-documented uses: prevention of cmv disease in high-risk solid-organ transplant recipients (kidney, heart, kidney-pancreas), treatment of cmv retinitis in patients with aids, reduction of cmv viral load and end-organ disease. 3 sources indexed (2004–2017), with 7 interaction records on file.
Core mechanism
Valganciclovir is hydrolyzed by intestinal and hepatic esterases to ganciclovir, the active moiety. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine. In CMV-infected cells it is initially phosphorylated by the viral protein kinase encoded by the UL97 gene, then converted to ganciclovir triphosphate by host cellular kinases. Ganciclovir triphosphate competitively inhibits the viral DNA polymerase (UL54) and is incorporated into viral DNA, slowing and ultimately terminating viral DNA chain elongation. Because phosphorylation is far more efficient in virus-infected cells, the active drug is concentrated where the virus is replicating.1,3
Oral bioavailability of ganciclovir from valganciclovir is roughly 60 percent and increases when taken with food, so doses should be taken with meals. Tablets and oral solution are not interchangeable on a milligram-for-milligram basis at all doses.
Nutrients this medication can lower over time, and what to replace.
Ganciclovir (the active moiety of valganciclovir) is a guanosine nucleoside analog that inhibits DNA synthesis and is markedly myelosuppressive, causing neutropenia, anemia, and thrombocytopenia. The resulting high turnover of bone marrow precursors increases demand on folate-dependent one-carbon metabolism for nucleotide synthesis, and functional folate status can become limiting during sustained marrow stress. This is a functional/relative depletion driven by hematopoietic demand rather than direct gut or renal loss.
Ganciclovir/valganciclovir can cause renal tubular dysfunction and is frequently co-administered in transplant recipients receiving calcineurin inhibitors (cyclosporine, tacrolimus), which produce renal magnesium wasting. The antiviral contributes to nephrotoxicity and electrolyte disturbance, and clinically relevant hypomagnesemia is reported in this population, partly attributable to increased urinary magnesium loss.
Ginkgo Biloba may increase bleeding tendency and can be a concern with Valganciclovir when valganciclovir causes thrombocytopenia or the patient is anticoagulated.
Recommendation: Avoid high-dose use unless the prescriber agrees; seek care for unusual bruising, bleeding, black stools, or severe headache.
Garlic Extract may increase bleeding tendency and can be a concern with Valganciclovir when valganciclovir causes thrombocytopenia or the patient is anticoagulated.
Recommendation: Avoid high-dose use unless the prescriber agrees; seek care for unusual bruising, bleeding, black stools, or severe headache.
Creatine can raise measured serum creatinine and complicate renal assessment for Valganciclovir, which depends on kidney function for dosing or toxicity monitoring.
Recommendation: Tell the prescriber about creatine use and avoid creatine loading during acute illness, kidney injury, or therapy requiring close renal dosing.
Valganciclovir (the oral prodrug of ganciclovir) commonly causes dose-limiting myelosuppression, including anemia. People taking it may be tempted to self-treat fatigue or a low hemoglobin with oral iron, but iron deficiency is frequently not the underlying cause of ganciclovir-associated anemia, which is typically due to direct bone marrow suppression. Empiric iron supplementation will not correct marrow-suppression anemia and may mask the need for dose reduction, growth-factor support, or transfusion.
Recommendation: Do not start oral iron for fatigue or anemia during valganciclovir therapy without first confirming true iron deficiency (ferritin, transferrin saturation) and discussing the cause of the anemia with the prescriber. Anemia during therapy should prompt a complete blood count and clinical review rather than self-treatment.
Valganciclovir frequently causes neutropenia and other cytopenias. High-dose or prolonged zinc supplementation can induce copper deficiency, which itself produces neutropenia and anemia. Combining chronic high-dose zinc with a known myelosuppressive antiviral can compound the risk of low neutrophil counts and complicate interpretation of the blood-count abnormalities that already require monitoring during therapy.
Recommendation: Avoid chronic high-dose zinc (generally above roughly 40 mg/day of elemental zinc) while on valganciclovir unless directed by a clinician. Keep any zinc intake within recommended daily amounts, and report new or worsening cytopenias so the cause can be sorted out.
Ganciclovir, the active form of valganciclovir, is renally cleared and can be nephrotoxic, with kidney impairment requiring dose reduction. Chronic high-dose vitamin C (gram-level doses) increases urinary oxalate and has been associated with calcium-oxalate kidney stones and, rarely, oxalate nephropathy. Combining habitual high-dose vitamin C with a renally cleared, potentially nephrotoxic antiviral adds an unnecessary kidney stressor in patients whose renal function directly governs safe drug dosing.
Recommendation: Avoid sustained high-dose vitamin C (more than about 1,000 mg/day) during valganciclovir therapy, especially in anyone with reduced kidney function, dehydration, or a history of kidney stones. Maintain good hydration and stay near the recommended daily intake from food and modest supplementation.
Valganciclovir is used heavily in immunosuppressed populations such as solid-organ and stem-cell transplant recipients, and it can deepen immune compromise through neutropenia. Live-organism probiotic supplements carry a small but real risk of bacteremia or fungemia in severely immunocompromised or neutropenic patients. The concern is not a chemical drug interaction but the heightened infection risk of ingesting live organisms in this vulnerable group.
Recommendation: Immunocompromised patients (transplant recipients, those with significant neutropenia) on valganciclovir should not start live probiotic supplements without clearing it with their transplant or infectious-disease team. Fermented foods and probiotics that are safe for the general public are not automatically safe during profound immunosuppression.
Numbered references. Citations throughout the page link here.
Once-daily valganciclovir was as effective as oral ganciclovir three times daily in preventing CMV disease in high-risk D+/R- transplant patients.
Ganciclovir requires UL97-mediated initial phosphorylation; ganciclovir triphosphate inhibits the UL54 viral DNA polymerase and terminates viral DNA synthesis.
Approved for CMV retinitis in AIDS and for prevention of CMV disease in high-risk kidney, heart, and kidney-pancreas transplant recipients; standard dosing 900 mg with renal adjustment.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
